Cai Jing Wang·2025-08-01 02:16Core Insights - The company has entered into an exclusive licensing agreement with Madrigal Pharmaceuticals for the development, production, and commercialization of the oral small molecule GLP-1 receptor agonist SYH2086 globally [1][2] - The agreement allows the company to retain rights to develop and sell other oral small molecule GLP-1 receptor agonist products in China while granting Madrigal exclusive global rights [1] - The total potential consideration for the agreement can reach up to $2.075 billion, including an upfront payment of $120 million and up to $1.955 billion in potential milestone payments based on development, regulatory, and commercial achievements, along with high double-digit royalties on annual net sales of SYH2086 [1] Product Details - SYH2086 is a clinical-stage candidate drug developed by the company with complete proprietary intellectual property, classified as a new type of oral small molecule GLP-1 receptor agonist [1] - GLP-1 receptor agonists are designed for the management of type 2 diabetes and obesity, functioning by promoting insulin secretion, inhibiting glucagon release, delaying gastric emptying, and reducing appetite, thus providing both glucose-lowering and weight-loss effects [1] Clinical Data - Preclinical data indicates that SYH2086 exhibits excellent in vitro agonistic activity and effective glucose-lowering and weight-loss effects in vivo, with a wide dose range linear pharmacokinetic behavior across different animal species and no significant safety risks [2]